Research Capital Corporation – Breathing Easier – Liftoff! – IPF Phase 2a Data Hits
ACTION: Maintaining SPECULATIVE BUY Rating and Target Price AGN reported topline results of a Phase 2a trial with ifenprodil in IPF patients with chronic cough – the idiopathic pulmonary fibrosis (IPF) data hit its endpoint -showing promising initial efficacy. We are maintaining a SPECULATIVE BUY rating. Our target price of C$25.00 is based on a probability-adjusted NPV analysis of ifenprodil.
DETAILS: Topline Phase 2a Results with Ifenprodil in IPF Patients with Chronic Cough
Design of the Trial: This open-label study enrolled 20 idiopathic pulmonary fibrosis (IPF) patients with chronic cough. Each patient received 12 wks of ifenprodil treatment (20mg, 3 times/day). The primary endpoints…